ARMP vs SMMT
ARMP: Armata Pharmaceuticals is pioneering the development of precision bacteriophage therapies as a targeted alternative to traditional broad-spectrum antibiotics for drug-resistant bacterial infections. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | ARMP | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.86 | $17.17 | |
| Market cap | $144M | $13.7B | |
| ROE FY2025, SEC XBRL | n/a | -163.9% | |
| ROA FY2025, SEC XBRL | -226.1% | -143.7% | SMMT higher |
| Debt / equity as of 2026-09-03 | 1.38 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-09-03 | +10.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.36 | 1.66 | |
| 1-year return as of 2026-10-08 close | +19.9% | -26.4% | ARMP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.